ID   ERBB3_HUMAN             Reviewed;        1342 AA.
AC   P21860; A8K6L6; B4DIK7; B4DV32; E9PDT8; Q9BUD7;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   10-MAY-2017, entry version 199.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-3;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER3;
DE   Flags: Precursor;
GN   Name=ERBB3; Synonyms=HER3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2687875; DOI=10.1073/pnas.86.23.9193;
RA   Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A.;
RT   "Isolation and characterization of ERBB3, a third member of the
RT   ERBB/epidermal growth factor receptor family: evidence for
RT   overexpression in a subset of human mammary tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9193-9197(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2164210; DOI=10.1073/pnas.87.13.4905;
RA   Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L.,
RA   Todaro G.J., Shoyab M.;
RT   "Molecular cloning and expression of an additional epidermal growth
RT   factor receptor-related gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4905-4909(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=7685162; DOI=10.1006/bbrc.1993.1542;
RA   Katoh M., Yazaki Y., Sugimura T., Terada M.;
RT   "c-erbB3 gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 192:1189-1197(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Hippocampus, Placenta, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors
RT   reveals a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [9]
RP   INTERACTION WITH PA2G4.
RX   PubMed=11325528; DOI=10.1016/S0303-7207(01)00387-2;
RA   Lessor T.J., Hamburger A.W.;
RT   "Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.";
RL   Mol. Cell. Endocrinol. 175:185-191(2001).
RN   [10]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [11]
RP   INTERACTION WITH CSPG5, AND FUNCTION.
RX   PubMed=15358134; DOI=10.1016/j.bbrc.2004.07.066;
RA   Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H.,
RA   Higashiyama S.;
RT   "Neuroglycan C, a novel member of the neuregulin family.";
RL   Biochem. Biophys. Res. Commun. 321:1045-1049(2004).
RN   [12]
RP   INTERACTION WITH PA2G4.
RX   PubMed=16832058; DOI=10.1073/pnas.0602923103;
RA   Liu Z., Ahn J.Y., Liu X., Ye K.;
RT   "Ebp1 isoforms distinctively regulate cell survival and
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10917-10922(2006).
RN   [13]
RP   INVOLVEMENT IN LCCS2.
RX   PubMed=17701904; DOI=10.1086/520770;
RA   Narkis G., Ofir R., Manor E., Landau D., Elbedour K., Birk O.S.;
RT   "Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a
RT   mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-
RT   kinase/Akt pathway.";
RL   Am. J. Hum. Genet. 81:589-595(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   FUNCTION, BINDING TO NRG1, IDENTIFICATION IN A COMPLEX WITH NRG1 AND
RP   INTEGRINS, AND PHOSPHORYLATION.
RX   PubMed=20682778; DOI=10.1074/jbc.M110.113878;
RA   Ieguchi K., Fujita M., Ma Z., Davari P., Taniguchi Y., Sekiguchi K.,
RA   Wang B., Takada Y.K., Takada Y.;
RT   "Direct binding of the EGF-like domain of neuregulin-1 to integrins
RT   ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB
RT   signaling.";
RL   J. Biol. Chem. 285:31388-31398(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686 AND SER-982, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 20-640, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-250; ASN-353; ASN-408; ASN-414; ASN-437; ASN-469;
RP   ASN-522 AND ASN-566.
RX   PubMed=12154198; DOI=10.1126/science.1074611;
RA   Cho H.S., Leahy D.J.;
RT   "Structure of the extracellular region of HER3 reveals an interdomain
RT   tether.";
RL   Science 297:1330-1333(2002).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 698-1019 IN COMPLEX WITH
RP   AMP-PNP, AND SUBUNIT.
RX   PubMed=20007378; DOI=10.1073/pnas.0912101106;
RA   Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J.;
RT   "Structural analysis of the catalytically inactive kinase domain of
RT   the human EGF receptor 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:21608-21613(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 684-1020 IN COMPLEX WITH
RP   AMP-PNP, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-742 AND TYR-868,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=20351256; DOI=10.1073/pnas.1002753107;
RA   Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A.;
RT   "ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze
RT   autophosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:7692-7697(2010).
RN   [21]
RP   STRUCTURE BY NMR OF 640-670, AND SUBUNIT.
RX   PubMed=21575594; DOI=10.1016/j.bbamem.2011.04.017;
RA   Mineev K.S., Khabibullina N.F., Lyukmanova E.N., Dolgikh D.A.,
RA   Kirpichnikov M.P., Arseniev A.S.;
RT   "Spatial structure and dimer-monomer equilibrium of the ErbB3
RT   transmembrane domain in DPC micelles.";
RL   Biochim. Biophys. Acta 1808:2081-2088(2011).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-20; LEU-30; MET-104; ILE-204;
RP   TRP-683; LEU-717; THR-744; ARG-998; CYS-1119; HIS-1127; ILE-1177 AND
RP   LYS-1254.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as
CC       cell surface receptor for neuregulins. Binds to neuregulin-1
CC       (NRG1) and is activated by it; ligand-binding increases
CC       phosphorylation on tyrosine residues and promotes its association
CC       with the p85 subunit of phosphatidylinositol 3-kinase
CC       (PubMed:20682778). May also be activated by CSPG5
CC       (PubMed:15358134). {ECO:0000269|PubMed:15358134,
CC       ECO:0000269|PubMed:20682778}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000269|PubMed:20351256}.
CC   -!- SUBUNIT: Monomer and homodimer. Heterodimer with each of the other
CC       ERBB receptors (Potential). Interacts with CSPG5
CC       (PubMed:15358134). Interacts with GRB7 (PubMed:9516479). Interacts
CC       with MUC1 (PubMed:12939402). Interacts with MYOC (By similarity).
CC       Interacts with isoform 2 of PA2G4 (PubMed:11325528,
CC       PubMed:16832058). Found in a ternary complex with NRG1 and
CC       ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:20682778).
CC       {ECO:0000250|UniProtKB:Q61526, ECO:0000269|PubMed:11325528,
CC       ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15358134,
CC       ECO:0000269|PubMed:16832058, ECO:0000269|PubMed:20682778,
CC       ECO:0000269|PubMed:9516479, ECO:0000305}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-720706, EBI-720706;
CC       P42684:ABL2; NbExp=10; IntAct=EBI-720706, EBI-1102694;
CC       P46108:CRK; NbExp=2; IntAct=EBI-720706, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-720706, EBI-910;
CC       P00533:EGFR; NbExp=12; IntAct=EBI-720706, EBI-297353;
CC       P04626:ERBB2; NbExp=25; IntAct=EBI-720706, EBI-641062;
CC       Q15303:ERBB4; NbExp=4; IntAct=EBI-720706, EBI-80371;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-720706, EBI-401755;
CC       Q14451:GRB7; NbExp=7; IntAct=EBI-720706, EBI-970191;
CC       P08631:HCK; NbExp=2; IntAct=EBI-720706, EBI-346340;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-720706, EBI-352572;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-720706, EBI-713635;
CC       Q02297-7:NRG1; NbExp=3; IntAct=EBI-720706, EBI-2460927;
CC       P42336:PIK3CA; NbExp=3; IntAct=EBI-720706, EBI-2116585;
CC       P27986:PIK3R1; NbExp=40; IntAct=EBI-720706, EBI-79464;
CC       O00459:PIK3R2; NbExp=16; IntAct=EBI-720706, EBI-346930;
CC       Q92569:PIK3R3; NbExp=22; IntAct=EBI-720706, EBI-79893;
CC       P19174:PLCG1; NbExp=4; IntAct=EBI-720706, EBI-79387;
CC       P20936:RASA1; NbExp=6; IntAct=EBI-720706, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-720706, EBI-7879749;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-720706, EBI-78835;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-720706, EBI-79084;
CC       P12931:SRC; NbExp=2; IntAct=EBI-720706, EBI-621482;
CC       P43405:SYK; NbExp=6; IntAct=EBI-720706, EBI-78302;
CC       Q63HR2:TNS2; NbExp=3; IntAct=EBI-720706, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=2; IntAct=EBI-720706, EBI-1220488;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=long form;
CC         IsoId=P21860-1; Sequence=Displayed;
CC       Name=2; Synonyms=short form;
CC         IsoId=P21860-2; Sequence=VSP_002893, VSP_002894;
CC       Name=3;
CC         IsoId=P21860-3; Sequence=VSP_041663, VSP_041664;
CC       Name=4;
CC         IsoId=P21860-4; Sequence=VSP_041662;
CC       Name=5;
CC         IsoId=P21860-5; Sequence=VSP_041661;
CC   -!- TISSUE SPECIFICITY: Epithelial tissues and brain.
CC   -!- DEVELOPMENTAL STAGE: Overexpressed in a subset of human mammary
CC       tumors.
CC   -!- DOMAIN: The cytoplasmic part of the receptor may interact with the
CC       SH2 or SH3 domains of many signal-transducing proteins.
CC   -!- PTM: Autophosphorylated (PubMed:20351256). Ligand-binding
CC       increases phosphorylation on tyrosine residues and promotes its
CC       association with the p85 subunit of phosphatidylinositol 3-kinase
CC       (PubMed:20682778). {ECO:0000269|PubMed:20351256,
CC       ECO:0000269|PubMed:20682778}.
CC   -!- DISEASE: Lethal congenital contracture syndrome 2 (LCCS2)
CC       [MIM:607598]: A form of lethal congenital contracture syndrome, an
CC       autosomal recessive disorder characterized by degeneration of
CC       anterior horn neurons, extreme skeletal muscle atrophy, and
CC       congenital non-progressive joint contractures (arthrogryposis).
CC       The contractures can involve the upper or lower limbs and/or the
CC       vertebral column, leading to various degrees of flexion or
CC       extension limitations evident at birth. LCCS2 patients manifest
CC       craniofacial/ocular findings, lack of hydrops, multiple pterygia,
CC       and fractures, as well as a normal duration of pregnancy and a
CC       unique feature of a markedly distended urinary bladder (neurogenic
CC       bladder defect). The phenotype suggests a spinal cord neuropathic
CC       etiology. {ECO:0000269|PubMed:17701904}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB3ID40479ch12q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29366; AAA35790.1; -; mRNA.
DR   EMBL; M34309; AAA35979.1; -; mRNA.
DR   EMBL; S61953; AAB26935.1; -; mRNA.
DR   EMBL; BT007226; AAP35890.1; -; mRNA.
DR   EMBL; AK291681; BAF84370.1; -; mRNA.
DR   EMBL; AK295650; BAG58519.1; -; mRNA.
DR   EMBL; AK300909; BAG62544.1; -; mRNA.
DR   EMBL; AC034102; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002706; AAH02706.1; -; mRNA.
DR   EMBL; BC082992; AAH82992.1; -; mRNA.
DR   CCDS; CCDS31833.1; -. [P21860-1]
DR   CCDS; CCDS44918.1; -. [P21860-2]
DR   PIR; A36223; A36223.
DR   PIR; JH0803; JH0803.
DR   RefSeq; NP_001005915.1; NM_001005915.1. [P21860-2]
DR   RefSeq; NP_001973.2; NM_001982.3. [P21860-1]
DR   UniGene; Hs.118681; -.
DR   UniGene; Hs.622058; -.
DR   PDB; 1M6B; X-ray; 2.60 A; A/B=20-640.
DR   PDB; 2L9U; NMR; -; A/B=639-670.
DR   PDB; 3KEX; X-ray; 2.80 A; A/B=698-1019.
DR   PDB; 3LMG; X-ray; 2.80 A; A/B=684-1020.
DR   PDB; 3P11; X-ray; 3.70 A; A=20-532.
DR   PDB; 4LEO; X-ray; 2.64 A; C=20-631.
DR   PDB; 4OTW; X-ray; 2.51 A; A=698-1020.
DR   PDB; 4P59; X-ray; 3.40 A; A=20-640.
DR   PDB; 4RIW; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIX; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIY; X-ray; 2.98 A; A/C=698-1020.
DR   PDB; 5CUS; X-ray; 3.20 A; A/B/C/D=20-641.
DR   PDBsum; 1M6B; -.
DR   PDBsum; 2L9U; -.
DR   PDBsum; 3KEX; -.
DR   PDBsum; 3LMG; -.
DR   PDBsum; 3P11; -.
DR   PDBsum; 4LEO; -.
DR   PDBsum; 4OTW; -.
DR   PDBsum; 4P59; -.
DR   PDBsum; 4RIW; -.
DR   PDBsum; 4RIX; -.
DR   PDBsum; 4RIY; -.
DR   PDBsum; 5CUS; -.
DR   ProteinModelPortal; P21860; -.
DR   SMR; P21860; -.
DR   BioGrid; 108377; 150.
DR   DIP; DIP-36441N; -.
DR   IntAct; P21860; 93.
DR   MINT; MINT-158484; -.
DR   STRING; 9606.ENSP00000267101; -.
DR   BindingDB; P21860; -.
DR   ChEMBL; CHEMBL5838; -.
DR   GuidetoPHARMACOLOGY; 1798; -.
DR   iPTMnet; P21860; -.
DR   PhosphoSitePlus; P21860; -.
DR   BioMuta; ERBB3; -.
DR   DMDM; 119534; -.
DR   MaxQB; P21860; -.
DR   PaxDb; P21860; -.
DR   PeptideAtlas; P21860; -.
DR   PRIDE; P21860; -.
DR   DNASU; 2065; -.
DR   Ensembl; ENST00000267101; ENSP00000267101; ENSG00000065361. [P21860-1]
DR   Ensembl; ENST00000411731; ENSP00000415753; ENSG00000065361. [P21860-2]
DR   Ensembl; ENST00000415288; ENSP00000408340; ENSG00000065361. [P21860-4]
DR   Ensembl; ENST00000551242; ENSP00000447510; ENSG00000065361. [P21860-3]
DR   GeneID; 2065; -.
DR   KEGG; hsa:2065; -.
DR   UCSC; uc001sjg.4; human. [P21860-1]
DR   CTD; 2065; -.
DR   DisGeNET; 2065; -.
DR   GeneCards; ERBB3; -.
DR   HGNC; HGNC:3431; ERBB3.
DR   HPA; CAB025331; -.
DR   HPA; HPA045396; -.
DR   MalaCards; ERBB3; -.
DR   MIM; 190151; gene.
DR   MIM; 607598; phenotype.
DR   neXtProt; NX_P21860; -.
DR   OpenTargets; ENSG00000065361; -.
DR   Orphanet; 137776; Lethal congenital contracture syndrome type 2.
DR   PharmGKB; PA27846; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P21860; -.
DR   KO; K05084; -.
DR   OMA; CYHHSLN; -.
DR   OrthoDB; EOG091G00IX; -.
DR   PhylomeDB; P21860; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   SignaLink; P21860; -.
DR   SIGNOR; P21860; -.
DR   ChiTaRS; ERBB3; human.
DR   EvolutionaryTrace; P21860; -.
DR   GeneWiki; ERBB3; -.
DR   GenomeRNAi; 2065; -.
DR   PRO; PR:P21860; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000065361; -.
DR   CleanEx; HS_ERBB3; -.
DR   ExpressionAtlas; P21860; baseline and differential.
DR   Genevisible; P21860; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0038132; F:neuregulin binding; IDA:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:BHF-UCL.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; ISS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:CAFA.
DR   GO; GO:0021545; P:cranial nerve development; ISS:BHF-UCL.
DR   GO; GO:0003197; P:endocardial cushion development; IEA:Ensembl.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:1901185; P:negative regulation of ERBB signaling pathway; TAS:Reactome.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IDA:BHF-UCL.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl.
DR   GO; GO:0055025; P:positive regulation of cardiac muscle tissue development; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:BHF-UCL.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0042127; P:regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; NAS:BHF-UCL.
DR   Gene3D; 3.80.20.20; -; 3.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Secreted; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1342       Receptor tyrosine-protein kinase erbB-3.
FT                                /FTId=PRO_0000016672.
FT   TOPO_DOM     20    643       Extracellular. {ECO:0000255}.
FT   TRANSMEM    644    664       Helical. {ECO:0000255}.
FT   TOPO_DOM    665   1342       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      709    966       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     715    723       ATP.
FT   NP_BIND     788    790       ATP.
FT   NP_BIND     834    839       ATP.
FT   ACT_SITE    834    834       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     742    742       ATP.
FT   MOD_RES     686    686       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     982    982       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD    126    126       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    250    250       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    414    414       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    437    437       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    469    469       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    522    522       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    566    566       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     29     56       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    156    183       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    186    194       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    190    202       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    210    218       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    214    226       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    227    235       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    231    243       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    246    255       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    259    286       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    290    301       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    305    320       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    323    327       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    500    509       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    504    517       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    520    529       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    533    549       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    552    565       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    556    573       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    576    585       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    589    610       {ECO:0000250}.
FT   DISULFID    613    621       {ECO:0000250}.
FT   DISULFID    617    629       {ECO:0000250}.
FT   VAR_SEQ       1    643       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041661.
FT   VAR_SEQ       1     59       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041662.
FT   VAR_SEQ     141    183       EILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGR
FT                                SC -> GQFPMVPSGLTPQPAQDWYLLDDDPRLLTLSASSK
FT                                VPVTLAAV (in isoform 2).
FT                                {ECO:0000303|PubMed:7685162}.
FT                                /FTId=VSP_002893.
FT   VAR_SEQ     184   1342       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7685162}.
FT                                /FTId=VSP_002894.
FT   VAR_SEQ     331    331       C -> F (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_041663.
FT   VAR_SEQ     332   1342       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_041664.
FT   VARIANT      20     20       S -> Y (in dbSNP:rs34379766).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042101.
FT   VARIANT      30     30       P -> L (in dbSNP:rs56017157).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042102.
FT   VARIANT     104    104       V -> M (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042103.
FT   VARIANT     204    204       T -> I (in dbSNP:rs56107455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042104.
FT   VARIANT     385    385       N -> S (in dbSNP:rs12320176).
FT                                /FTId=VAR_049710.
FT   VARIANT     683    683       R -> W (in dbSNP:rs56387488).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042105.
FT   VARIANT     717    717       S -> L (in dbSNP:rs35961836).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042106.
FT   VARIANT     744    744       I -> T (in dbSNP:rs55787439).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042107.
FT   VARIANT     998    998       K -> R (in dbSNP:rs56259600).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042108.
FT   VARIANT    1119   1119       S -> C (in dbSNP:rs773123).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042109.
FT   VARIANT    1127   1127       R -> H (in dbSNP:rs2271188).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042110.
FT   VARIANT    1177   1177       L -> I (in dbSNP:rs55699040).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042111.
FT   VARIANT    1254   1254       T -> K (in dbSNP:rs55709407).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042112.
FT   VARIANT    1271   1271       G -> S (in dbSNP:rs11171743).
FT                                /FTId=VAR_049711.
FT   MUTAGEN     742    742       K->M: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:20351256}.
FT   MUTAGEN     868    868       Y->E: Strongly reduced tyrosine
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:20351256}.
FT   CONFLICT    560    560       E -> G (in Ref. 2; AAA35979).
FT                                {ECO:0000305}.
FT   CONFLICT    684    684       G -> S (in Ref. 5; BAF84370).
FT                                {ECO:0000305}.
FT   CONFLICT   1064   1064       E -> G (in Ref. 2; AAA35979).
FT                                {ECO:0000305}.
FT   CONFLICT   1078   1078       C -> S (in Ref. 5; BAG62544).
FT                                {ECO:0000305}.
FT   CONFLICT   1163   1163       D -> G (in Ref. 5; BAF84370).
FT                                {ECO:0000305}.
FT   STRAND       28     30       {ECO:0000244|PDB:4LEO}.
FT   HELIX        43     53       {ECO:0000244|PDB:4LEO}.
FT   STRAND       58     61       {ECO:0000244|PDB:1M6B}.
FT   STRAND       63     67       {ECO:0000244|PDB:1M6B}.
FT   HELIX        75     79       {ECO:0000244|PDB:1M6B}.
FT   STRAND       82     85       {ECO:0000244|PDB:1M6B}.
FT   STRAND       87     91       {ECO:0000244|PDB:1M6B}.
FT   STRAND       95     98       {ECO:0000244|PDB:1M6B}.
FT   TURN        112    114       {ECO:0000244|PDB:1M6B}.
FT   STRAND      115    120       {ECO:0000244|PDB:1M6B}.
FT   STRAND      125    128       {ECO:0000244|PDB:4LEO}.
FT   STRAND      133    135       {ECO:0000244|PDB:1M6B}.
FT   STRAND      141    144       {ECO:0000244|PDB:5CUS}.
FT   STRAND      146    150       {ECO:0000244|PDB:1M6B}.
FT   TURN        158    160       {ECO:0000244|PDB:1M6B}.
FT   HELIX       163    166       {ECO:0000244|PDB:1M6B}.
FT   STRAND      174    178       {ECO:0000244|PDB:1M6B}.
FT   HELIX       188    190       {ECO:0000244|PDB:4LEO}.
FT   STRAND      194    198       {ECO:0000244|PDB:1M6B}.
FT   STRAND      214    216       {ECO:0000244|PDB:1M6B}.
FT   STRAND      218    222       {ECO:0000244|PDB:1M6B}.
FT   HELIX       223    225       {ECO:0000244|PDB:5CUS}.
FT   STRAND      231    233       {ECO:0000244|PDB:1M6B}.
FT   STRAND      235    239       {ECO:0000244|PDB:1M6B}.
FT   HELIX       240    242       {ECO:0000244|PDB:1M6B}.
FT   STRAND      243    251       {ECO:0000244|PDB:1M6B}.
FT   STRAND      254    258       {ECO:0000244|PDB:1M6B}.
FT   STRAND      262    265       {ECO:0000244|PDB:1M6B}.
FT   TURN        267    269       {ECO:0000244|PDB:1M6B}.
FT   STRAND      270    274       {ECO:0000244|PDB:1M6B}.
FT   STRAND      280    282       {ECO:0000244|PDB:1M6B}.
FT   STRAND      285    289       {ECO:0000244|PDB:1M6B}.
FT   STRAND      295    297       {ECO:0000244|PDB:1M6B}.
FT   STRAND      300    304       {ECO:0000244|PDB:1M6B}.
FT   STRAND      309    314       {ECO:0000244|PDB:1M6B}.
FT   STRAND      317    322       {ECO:0000244|PDB:1M6B}.
FT   STRAND      324    326       {ECO:0000244|PDB:4LEO}.
FT   STRAND      330    332       {ECO:0000244|PDB:1M6B}.
FT   STRAND      338    342       {ECO:0000244|PDB:5CUS}.
FT   TURN        345    347       {ECO:0000244|PDB:1M6B}.
FT   HELIX       348    351       {ECO:0000244|PDB:1M6B}.
FT   STRAND      356    363       {ECO:0000244|PDB:1M6B}.
FT   HELIX       365    369       {ECO:0000244|PDB:1M6B}.
FT   TURN        372    375       {ECO:0000244|PDB:1M6B}.
FT   HELIX       381    389       {ECO:0000244|PDB:1M6B}.
FT   STRAND      392    395       {ECO:0000244|PDB:1M6B}.
FT   STRAND      397    400       {ECO:0000244|PDB:1M6B}.
FT   HELIX       410    412       {ECO:0000244|PDB:1M6B}.
FT   STRAND      425    433       {ECO:0000244|PDB:1M6B}.
FT   STRAND      451    457       {ECO:0000244|PDB:1M6B}.
FT   HELIX       465    467       {ECO:0000244|PDB:4LEO}.
FT   HELIX       470    473       {ECO:0000244|PDB:1M6B}.
FT   STRAND      482    488       {ECO:0000244|PDB:1M6B}.
FT   HELIX       490    493       {ECO:0000244|PDB:1M6B}.
FT   TURN        494    497       {ECO:0000244|PDB:1M6B}.
FT   STRAND      509    513       {ECO:0000244|PDB:1M6B}.
FT   HELIX       514    516       {ECO:0000244|PDB:1M6B}.
FT   STRAND      517    527       {ECO:0000244|PDB:1M6B}.
FT   STRAND      529    531       {ECO:0000244|PDB:1M6B}.
FT   STRAND      534    536       {ECO:0000244|PDB:1M6B}.
FT   STRAND      538    540       {ECO:0000244|PDB:1M6B}.
FT   STRAND      542    545       {ECO:0000244|PDB:1M6B}.
FT   STRAND      548    551       {ECO:0000244|PDB:1M6B}.
FT   STRAND      560    562       {ECO:0000244|PDB:5CUS}.
FT   STRAND      564    570       {ECO:0000244|PDB:1M6B}.
FT   STRAND      573    581       {ECO:0000244|PDB:1M6B}.
FT   STRAND      584    588       {ECO:0000244|PDB:1M6B}.
FT   STRAND      591    594       {ECO:0000244|PDB:4LEO}.
FT   STRAND      600    604       {ECO:0000244|PDB:1M6B}.
FT   STRAND      608    612       {ECO:0000244|PDB:1M6B}.
FT   STRAND      622    625       {ECO:0000244|PDB:1M6B}.
FT   HELIX       626    628       {ECO:0000244|PDB:4LEO}.
FT   HELIX       641    670       {ECO:0000244|PDB:2L9U}.
FT   HELIX       706    708       {ECO:0000244|PDB:4OTW}.
FT   STRAND      709    716       {ECO:0000244|PDB:4OTW}.
FT   STRAND      722    728       {ECO:0000244|PDB:4OTW}.
FT   STRAND      731    733       {ECO:0000244|PDB:3LMG}.
FT   STRAND      737    744       {ECO:0000244|PDB:4OTW}.
FT   TURN        747    749       {ECO:0000244|PDB:4OTW}.
FT   STRAND      753    755       {ECO:0000244|PDB:4RIY}.
FT   HELIX       758    764       {ECO:0000244|PDB:4OTW}.
FT   STRAND      774    778       {ECO:0000244|PDB:4OTW}.
FT   STRAND      780    788       {ECO:0000244|PDB:4OTW}.
FT   HELIX       795    802       {ECO:0000244|PDB:4OTW}.
FT   HELIX       803    805       {ECO:0000244|PDB:4OTW}.
FT   HELIX       808    827       {ECO:0000244|PDB:4OTW}.
FT   HELIX       837    839       {ECO:0000244|PDB:4OTW}.
FT   STRAND      840    846       {ECO:0000244|PDB:4OTW}.
FT   STRAND      848    850       {ECO:0000244|PDB:4OTW}.
FT   HELIX       855    858       {ECO:0000244|PDB:4OTW}.
FT   HELIX       865    868       {ECO:0000244|PDB:4RIY}.
FT   TURN        870    872       {ECO:0000244|PDB:4RIY}.
FT   HELIX       875    877       {ECO:0000244|PDB:4OTW}.
FT   HELIX       880    885       {ECO:0000244|PDB:4OTW}.
FT   HELIX       890    905       {ECO:0000244|PDB:4OTW}.
FT   TURN        911    914       {ECO:0000244|PDB:4OTW}.
FT   HELIX       917    919       {ECO:0000244|PDB:4OTW}.
FT   HELIX       920    925       {ECO:0000244|PDB:4OTW}.
FT   HELIX       938    947       {ECO:0000244|PDB:4OTW}.
FT   TURN        952    954       {ECO:0000244|PDB:4OTW}.
FT   HELIX       958    968       {ECO:0000244|PDB:4OTW}.
FT   HELIX       972    975       {ECO:0000244|PDB:4OTW}.
FT   STRAND      980    983       {ECO:0000244|PDB:3KEX}.
SQ   SEQUENCE   1342 AA;  148098 MW;  7201E7F66CA374BD CRC64;
     MRANDALQVL GLLFSLARGS EVGNSQAVCP GTLNGLSVTG DAENQYQTLY KLYERCEVVM
     GNLEIVLTGH NADLSFLQWI REVTGYVLVA MNEFSTLPLP NLRVVRGTQV YDGKFAIFVM
     LNYNTNSSHA LRQLRLTQLT EILSGGVYIE KNDKLCHMDT IDWRDIVRDR DAEIVVKDNG
     RSCPPCHEVC KGRCWGPGSE DCQTLTKTIC APQCNGHCFG PNPNQCCHDE CAGGCSGPQD
     TDCFACRHFN DSGACVPRCP QPLVYNKLTF QLEPNPHTKY QYGGVCVASC PHNFVVDQTS
     CVRACPPDKM EVDKNGLKMC EPCGGLCPKA CEGTGSGSRF QTVDSSNIDG FVNCTKILGN
     LDFLITGLNG DPWHKIPALD PEKLNVFRTV REITGYLNIQ SWPPHMHNFS VFSNLTTIGG
     RSLYNRGFSL LIMKNLNVTS LGFRSLKEIS AGRIYISANR QLCYHHSLNW TKVLRGPTEE
     RLDIKHNRPR RDCVAEGKVC DPLCSSGGCW GPGPGQCLSC RNYSRGGVCV THCNFLNGEP
     REFAHEAECF SCHPECQPME GTATCNGSGS DTCAQCAHFR DGPHCVSSCP HGVLGAKGPI
     YKYPDVQNEC RPCHENCTQG CKGPELQDCL GQTLVLIGKT HLTMALTVIA GLVVIFMMLG
     GTFLYWRGRR IQNKRAMRRY LERGESIEPL DPSEKANKVL ARIFKETELR KLKVLGSGVF
     GTVHKGVWIP EGESIKIPVC IKVIEDKSGR QSFQAVTDHM LAIGSLDHAH IVRLLGLCPG
     SSLQLVTQYL PLGSLLDHVR QHRGALGPQL LLNWGVQIAK GMYYLEEHGM VHRNLAARNV
     LLKSPSQVQV ADFGVADLLP PDDKQLLYSE AKTPIKWMAL ESIHFGKYTH QSDVWSYGVT
     VWELMTFGAE PYAGLRLAEV PDLLEKGERL AQPQICTIDV YMVMVKCWMI DENIRPTFKE
     LANEFTRMAR DPPRYLVIKR ESGPGIAPGP EPHGLTNKKL EEVELEPELD LDLDLEAEED
     NLATTTLGSA LSLPVGTLNR PRGSQSLLSP SSGYMPMNQG NLGESCQESA VSGSSERCPR
     PVSLHPMPRG CLASESSEGH VTGSEAELQE KVSMCRSRSR SRSPRPRGDS AYHSQRHSLL
     TPVTPLSPPG LEEEDVNGYV MPDTHLKGTP SSREGTLSSV GLSSVLGTEE EDEDEEYEYM
     NRRRRHSPPH PPRPSSLEEL GYEYMDVGSD LSASLGSTQS CPLHPVPIMP TAGTTPDEDY
     EYMNRQRDGG GPGGDYAAMG ACPASEQGYE EMRAFQGPGH QAPHVHYARL KTLRSLEATD
     SAFDNPDYWH SRLFPKANAQ RT
//
